Last reviewed · How we verify
HRS-9057
At a glance
| Generic name | HRS-9057 |
|---|---|
| Sponsor | Fujian Shengdi Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention (PHASE2)
- A Study of HRS-9057 in Patients With Heart Failure and Volume Overload (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-9057 CI brief — competitive landscape report
- HRS-9057 updates RSS · CI watch RSS
- Fujian Shengdi Pharmaceutical Co., Ltd. portfolio CI